Former Elan boss Kelly Martin to take over as chief executive of Malin. Photo: Brenda Fitzsimons/The Irish Times

Irish life sciences investment firm Malin completed its initial series of asset purchases with two more investments on Monday and said director and fo(...)

Immunocore, which was spun out of Oxford University in 2008, is developing novel T cell receptor (TCR) based therapies with the potential to treat a variety of cancers, viral infections and autoimmune diseases

Malin, the Irish-based company set up by a number of former Elan executives to invest in privately held life science assets, has invested $80 million (...)

The announcement marks Malin’s first new asset following its stock exchange debut earlier this year

Malin, an Irish-based company set up by a number of former Elan executives to invest in privately held life science assets, has invested $35 million a(...)

Malin has said it will invest in companies for which an initial public offering (IPO) or trade sale is premature

Leading British fund manager Neil Woodford and the Irish state’s new strategic investment fund are among the investors who have committed to purchasin(...)

Malin has decided to target the funding needs of privately held early-stage life sciences business.

The Elan gene pool delivers once again. It would be wrong to suggest that the business – since subsumed into generics and over-the-counter specialist (...)

Former Elan chief executive Kelly Martin (pictured) and chairman Bob Ingram, who sold the Irish stock market stalwart to Perrigo for $8.6 billion in 2013, will sit on the board of Malin

Malin, an Irish company set up by a number of former Elan executives to invest in privately held life science assets, said it plans to raise between €(...)

Kinsale Capital Managent, the Dublin hedge fund manager run by the low-key, high-powered former Merrill Lynch bankers Gearoid Doyle and Seán Ó’Flannag(...)

Elan put itself up for sale in June after rejecting a number of hostile bids from private equity firm Royal Pharma. Photograph:John Cogill/Bloomberg News.

Biotech company Elan reported a $13.8 million loss in the third quarter as costs associated with the proposed takeover by pharmaceuticals firm Perr(...)

British business secretary Vince Cable said he thought it probable the exchequer would retain its 81 per cent shareholding in RBS for the majority of the next parliament. Photograph: Stefan Rousseau/PA Wire

British business minister Vince Cable has indicated that Ulster Bank parent RBS will be in public hands for another five years, according to the Sunda(...)

Elan chief executive Kelly Martin, a former  Merrill Lynch banker, took the helm in 2003, drastically paring down the company and opting to focus on the development of multiple sclerosis drug Tysabri.  Photograph: Alan Betson

The sale of Elan to Perrigo marks the end of a rollercoaster ride for the Irish drugmaker, which has fended off three takeover bids by private equity (...)